These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Institute of Medicine. Panel to Feds: hands off radioisotopes. Wolfgang L Science; 1995 Dec; 270(5244):1918. PubMed ID: 8533079 [No Abstract] [Full Text] [Related]
3. Regulating the tools of nuclear medicine. Hecht A FDA Consum; 1978 May; 12(4):6-12. PubMed ID: 10307464 [No Abstract] [Full Text] [Related]
4. Society sues NRC over radiopharmacy rule. Kotz D J Nucl Med; 1995 Mar; 36(3):14N-15N, 20N-21N. PubMed ID: 7884491 [No Abstract] [Full Text] [Related]
5. Regulation of the medical uses of radioisotopes; statement of general policy. Fed Regist; 1979 Feb; 44(29 1):8242-5. PubMed ID: 10239967 [No Abstract] [Full Text] [Related]
6. Nuclear cardiology news update. ASNC news. President's message. American Society of Nuclear Cardiology. Cerqueira MD J Nucl Cardiol; 1998; 5(1):113-4. PubMed ID: 9504882 [No Abstract] [Full Text] [Related]
7. Is there life in MARS? Nucl Med Commun; 2007 May; 28(5):425-6. PubMed ID: 17414895 [No Abstract] [Full Text] [Related]
8. Ensuring the future of nuclear medicine and molecular imaging. Atcher RW J Nucl Med; 2008 Oct; 49(10):27N, 32N. PubMed ID: 18832119 [No Abstract] [Full Text] [Related]
9. [Nuclear medicine 2001 and "Guidelines for use of radioactivity in medicine": consequences for nuclear medicine]. Reiners C; Schicha H Nuklearmedizin; 2002; 41(4):168-70. PubMed ID: 12224399 [No Abstract] [Full Text] [Related]
10. Preparation, transfer for commercial distribution, and use of byproduct material for medical use--NRC. Final rule; clarification. Fed Regist; 1995 Jan; 60(2 Pt 1):322-5. PubMed ID: 10139994 [TBL] [Abstract][Full Text] [Related]
11. Constants for calculating ambient and directional dose equivalents from radionuclide point sources. Groenewald WA; Wasserman HJ Health Phys; 1990 May; 58(5):655-8. PubMed ID: 2341257 [No Abstract] [Full Text] [Related]
12. The regulation of radiopharmaceuticals. Conway JJ JAMA; 1985 Jun; 253(21):3093. PubMed ID: 3999291 [No Abstract] [Full Text] [Related]
13. Targeted radionuclide therapy: proceedings of a joint workshop hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging. Fahey F; Zukotynski K; Capala J; Knight N; J Nucl Med; 2014 Feb; 55(2):337-48. PubMed ID: 24396032 [No Abstract] [Full Text] [Related]
14. Regulatory issues are primary focus for nuclear medicine groups. Nichols D J Nucl Med; 1997 Feb; 38(2):17N. PubMed ID: 9025728 [No Abstract] [Full Text] [Related]
15. The status of radiopharmacy as viewed by nuclear medicine department directors. Cruz PM; Winship HW Hosp Pharm; 1977 Jul; 12(7):342-3, 346, 356. PubMed ID: 10236487 [No Abstract] [Full Text] [Related]
16. A quality-control system for short-lived radiopharmaceuticals. Crews MC; Quinn JL; Bryant N J Nucl Med; 1969 Aug; 10(8):558-9. PubMed ID: 5791624 [No Abstract] [Full Text] [Related]
17. Medical use of byproduct material; policy statement, revision. Nuclear Regulatory Commission. Final policy statement; revision. Fed Regist; 2000 Aug; 65(150):47654-60. PubMed ID: 11067710 [TBL] [Abstract][Full Text] [Related]
18. Looking to the Future: The ABNM in the Next 10 Years. Segall GM J Nucl Med; 2016 Feb; 57(2):12N. PubMed ID: 26833908 [No Abstract] [Full Text] [Related]
19. The American Board of Nuclear Medicine, Inc.: Fifteen years of growth and progress. Ross JF J Nucl Med; 1986 Jun; 27(6):861-2. PubMed ID: 3712099 [No Abstract] [Full Text] [Related]
20. The Master of Science in radiopharmacy. Wolf W; Tubis M; Kawada TK Am Pharm; 1981 Oct; NS21(10):41-3. PubMed ID: 7340491 [No Abstract] [Full Text] [Related] [Next] [New Search]